安科生物：“AK2017注射液”预计明年年初可启动III期临床试验

Core Viewpoint - The company, Anke Bio (300009), reported that its self-developed "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein injection) is progressing well in clinical trials, having completed the enrollment for Phase II trials and submitted a supplementary application for Phase III trials, which are expected to commence in early next year [1] Group 1 - The company has successfully completed the enrollment for Phase II clinical trials of AK2017 Injection [1] - A supplementary application for Phase III clinical trials has been submitted [1] - The initiation of Phase III clinical trials is anticipated to start in early next year [1]